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1. INTRODUCTION {#cam42902-sec-0005}
===============

Laryngeal carcinoma (LC) ranks second among the most common cancers in the head and neck region, with an estimated incidence of 82 000 deaths and 151 000 new cases annually around the world.[1](#cam42902-bib-0001){ref-type="ref"} According to its anatomic subsites, laryngeal cancer is generally divided into glottic, supraglottic, and subglottic carcinoma with squamous cell cancer as the vast majority of histological type.[2](#cam42902-bib-0002){ref-type="ref"} With public awareness of excessive alcohol consumption and smoking as major predisposing factors, the incidence of laryngeal carcinoma has decreased over the past decade.[3](#cam42902-bib-0003){ref-type="ref"} However, according to a retrospective study from the US National Cancer Data Base (NCDB), the survival outcomes of laryngeal cancer patients have unexpectedly declined, whereas that of the most other tumor locations have improved.[4](#cam42902-bib-0004){ref-type="ref"}

Surgical resection remains an integral part of the treatment of LC with the emphasis on maximal oncologic control and optimal functional outcomes, including partial or total laryngectomy.[5](#cam42902-bib-0005){ref-type="ref"} In addition to surgery, adjuvant therapy is reckoned as an essential supplementary therapy for subclinical foci elimination, however, inappropriate adjuvant therapy may induce adverse effects for patients, including tissue necrosis, laryngeal edema xerostomia, trismus, and fibrosis.[6](#cam42902-bib-0006){ref-type="ref"} To date, the values of adjuvant therapies, including radiotherapy, chemotherapy, and chemoradiotherapy, remain controversial, partially due to the failure to select suitable LC patients.

Several previous studies have demonstrated the pN stage as a prognostic predictor and an efficient indicator for adjuvant therapy, which is mainly based on the number of metastatic lymph nodes and extra‐nodal extension (ENE).[7](#cam42902-bib-0007){ref-type="ref"}, [8](#cam42902-bib-0008){ref-type="ref"} However, a sufficient number of the examined lymph node is key to ensure the precise nodal staging. The number of examined lymph nodes (ELNs) can reflect the extent of lymphadenectomy and has been reported to be associated with oncological outcomes in several cancers.[9](#cam42902-bib-0009){ref-type="ref"}, [10](#cam42902-bib-0010){ref-type="ref"} Some studies also reported that the ratio of metastatic lymph nodes (MLNR) is a prognostic factor in certain tumors, including esophageal carcinoma and medullary thyroid cancer.[11](#cam42902-bib-0011){ref-type="ref"}, [12](#cam42902-bib-0012){ref-type="ref"}

In this study, we aimed to investigate the prognostic value of ELNs and MLNR for patients with laryngeal cancer who had undergone laryngectomy and lymphadenectomy. This study also explored the predictive value of the combination of ELNs, MLNR, and other clinicopathological features in the decision making of adjuvant therapy.

2. METHODS {#cam42902-sec-0006}
==========

2.1. Data source and collection {#cam42902-sec-0007}
-------------------------------

Data of patients diagnosed with laryngeal carcinoma (site code C32.0, C32.1, C32.2 C32.3, and C32.8) diagnosed from 2004 to 2015 were collected from the Surveillance, Epidemiology, and End Results (SEER) database, which is an authoritative information source affiliated to the National Cancer Institute (NCI) and is considered to be the golden standard for tumor clinical and pathological information collection worldwide.[13](#cam42902-bib-0013){ref-type="ref"} The extent of surgery was evaluated using regional nodes positive (1988+) and RX Summ‐Surg Prim Site (1998+). Only patients who received partial or total laryngectomy as their primary therapy and diagnosed with positive histology were included in the patient cohort. Patients were excluded if the following criteria were involved: (a) unknown/obscure follow‐up time; (b) diagnosed autopsy/death certificate only (DCO); (c) not the first tumor; (d) distant metastasis; (e) no lymphadenectomy or ELNs = 0; (f) unknown information on extracted data. Patients with overall survival ≤3 months were also excluded to reduce the potential bias causing by heterogeneity in treatment quality and perioperative care.

Information regarding age at diagnosis, race, gender, primary location, differentiated grade, American Joint Committee on Cancer (AJCC) TNM staging system (6th/7th edition), tumor size, number of metastatic lymph nodes, number of examined lymph nodes, therapy details (surgery record and adjuvant treatment record), and oncological outcomes were collected from the SEER database. In this study, overall survival, which was defined as the period from histological diagnosis date to the date of all‐cause of death or the last follow‐up time, was defined as the endpoint for LC patients.

2.2. Statistical analysis {#cam42902-sec-0008}
-------------------------

In the baseline characteristics, categorical variables were described as frequency and percentage and continuous variables were represented by the medians. The X‐tile program (Yale University School of Medicine, New Haven, CT, USA) was used to define the optimal cut‐off points for ELNs and MLNR with minimum *P* values for the log‐rank test and the highest specificity and sensitivity. Multivariate cox proportional hazards regression was performed to identify potential prognostic factors. Hazard ratios (HRs) and 95% confidence intervals (CIs) were also calculated. A novel survival‐predicting model was established. The predicting performance of this model was evaluated by the calibration curve and the Harrell\'s concordance index (C‐index). The Kaplan‐Meier analysis and the log‐rank tests were used to compare the survival differences between subgroups.

All statistical analyses above were performed using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). R (version 3.5.1; <https://www.r%2010project.org>) was used to establish and validate the predicting model. All analyses were two‐tailed, a *P*‐value \< .05 was considered as statistically significant.

3. RESULTS {#cam42902-sec-0009}
==========

3.1. Clinical characteristics of patients {#cam42902-sec-0010}
-----------------------------------------

After meeting the preset criteria, including without exact follow‐up time; autopsy/death certificate only (DCO), a total of 5746 cases receiving partial or total laryngectomy between January 2004 and December 2015 were retrieved from the SEER database. Then patients without lymphadenectomy or without exactly ELNs/LNR (n = 1793), with unknown cause of death and not first tumor (n = 780), unknown information on basic variables (race, differentiation grade, tumor location, TNM stage or tumor size \[n = 941\]), and patients with overall survival ≤3 months (n = 73) and patients with distant metastases (n = 37) were excluded.

Overall, a total of 2122 patients with resected laryngeal carcinoma (LC) were retrieved from the SEER database. The clinical and pathological characteristics of the patient cohort are summarized in Table [1](#cam42902-tbl-0001){ref-type="table"}. Nearly half of the patients (n = 1062) had metastatic lymph nodes. The mean ELNs was 41 (range from 1 to 97), and the mean LNR was 0.066 (range from 0 to 1). Partial laryngectomy was performed in 476 patients and total laryngectomy in 1646 patients. Of 1512 patients received adjuvant therapy, including radiotherapy (n = 816), chemotherapy (n = 36), and chemoradiotherapy (n = 660). The median age at diagnosis was 59 (range from 16 to 92).

###### 

Clinical characteristics of patients with resected laryngeal carcinoma

                             Total   Training set   Testing set   *P* value                 
  -------------------------- ------- -------------- ------------- ----------- ------ ------ ------
  Age                                                                                       
  ≤50                        269     12.7           206           13.9        63     9.9    .001
  (50,65)                    1181    55.7           789           53.1        392    61.5   
  \>65                       672     31.7           490           33.0        182    28.6   
  Race                                                                                      
  White                      1621    76.4           1143          77.0        478    75.0   .052
  Black                      412     19.4           290           19.5        122    19.2   
  Other                      89      4.2            52            3.5         37     5.8    
  Sex                                                                                       
  Female                     400     18.9           283           19.1        117    18.4   .762
  Male                       1722    81.1           1202          80.9        520    81.6   
  Year of diagnosis                                                                         
  ≤2010                      1189    56.0           841           56.6        348    54.6   .417
  \>2010                     933     44.0           644           43.3        289    45.4   
  Primary location                                                                          
  Supraglottic               1006    47.4           701           47.2        305    47.9   .290
  Glottic                    810     38.2           556           37.4        254    39.9   
  Subglottic                 88      4.1            65            4.4         23     3.6    
  Other                      218     10.3           163           11.0        55     8.6    
  Histologic type                                                                           
  Squamous cell              2048    96.5           1432          96.4        616    96.7   .798
  Other                      74      3.5            53            3.6         21     3.3    
  Grade                                                                                     
  Well                       155     7.3            110           7.4         45     7.1    .113
  Moderately                 1271    59.9           887           59.7        385    60.4   
  Poorly                     677     31.9           480           32.2        197    30.9   
  Undifferentiated           18      0.8            8             0.5         10     1.6    
  T classification                                                                          
  T1                         141     6.6            98            6.6         43     6.8    .244
  T2                         266     12.5           182           12.3        84     13.2   
  T3                         554     26.1           372           25.1        182    28.6   
  T4                         1161    54.7           833           56.1        328    51.5   
  ELNs                                                                                      
  Median (range)             40      0‐97           39            0‐97        41     0‐97   .167
  MLNR                                                                                      
  Median (range)             0.01    0‐1            0.01          0‐1         0.01   0‐1    .106
  Treatment                                                                                 
  With adjuvant therapy      610     28.7           443           29.8        167    26.2   .094
  Without adjuvant therapy   1512    71.3           1042          70.2        470    73.8   
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3.2. Identification of the cut‐off points for examined lymph nodes number and metastatic lymph nodes ratio {#cam42902-sec-0011}
----------------------------------------------------------------------------------------------------------

The X‐tile program was applied to analyze the data of LC patients from the SEER database and to determine the optimal cut‐off values for ELNs and MLNR. The whole patient cohort was randomly divided into a training set containing 1485 patients (70%), and a validating set including 637 patients (30%). The two sets were comparable in the clinical and oncological characteristics (shown in Table [1](#cam42902-tbl-0001){ref-type="table"}).

For patients in the training set, ELNs and MLNR were enrolled into the X‐tile program for analysis. The results showed that 50 was the optimal cut‐off values for ELNs (*P*‐value \< .001, Figure [1](#cam42902-fig-0001){ref-type="fig"}A). And the best cut‐off values for MLNR were 0 and 0.065 (*P*‐value \< .001, Figure [1](#cam42902-fig-0001){ref-type="fig"}B). Univariate and multivariate analysis showed that ELNs (*P* = .006), MLNR (*P* \< .001), age (*P* \< .001), T stage (*P* \< .001) were independent prognostic factors for overall survival in patients with resected laryngeal cancer as listed in Table [2](#cam42902-tbl-0002){ref-type="table"}.

![X‐tile analysis determining optimal ELNs and MLNR cut‐off values based on the overall survival. (A) ELNs: 50; (B) MLNR: 0 and 6.5%](CAM4-9-3006-g001){#cam42902-fig-0001}

###### 

Univariate and multivariate analysis of risk factors for overall survival in patients who underwent laryngectomy and lymphadenectomy

                     Univariate analysis   Multivariate analysis                         
  ------------------ --------------------- ----------------------- --------------------- ------
  Age                                                                                    
  ≤50                (Ref)                                         (Ref)                  
  (50,65)            1.456 (1.155‐1.836)   .001                    1.292 (1.023‐1.632)   .031
  \>65               2.085 (1.643‐2.645)   .000                    1.877 (1.474‐2.390)   .000
  Race                                                                                   
  White              (Ref)                                                                
  Black              1.151 (0.970‐1.366)   .107                                           
  Other              1.079 (0.733‐1.587)   .700                                           
  Sex                                                                                    
  Female             (Ref)                                                                
  Male               1.161 (0.968‐1.391)   .107                                           
  Primary location                                                                       
  Supraglottic       (Ref)                                                                
  Glottic            0.912 (0.782‐1.063)   .238                                           
  Subglottic         1.059 (0.752‐1.492)   .742                                           
  Other              1.207 (0.963‐1.512)   .103                                           
  Histologic type                                                                        
  Squamous cell      (Ref)                                                                
  Other              1.374 (0.974‐1.938)   .070                                           
  Grade                                                                                  
  Well               (Ref)                                         (Ref)                  
  Moderately         1.497 (1.087‐2.060)   .013                    1.368 (0.991‐1.887)   .057
  Poorly             1.853 (1.335‐2.572)   .000                    1.432 (1.025‐1.999)   .035
  Undifferentiated   2.728 (1.158‐6.428)   .022                    1.884 (0.794‐4.469)   .151
  T classification                                                                       
  T1                 (Ref)                                         (Ref)                  
  T2                 1.716 (1.148‐2.565)   .008                    1.625 (1.085‐2.434)   .019
  T3                 2.085 (1.442‐3.016)   .000                    1.894 (1.308‐2.743)   .001
  T4                 2.489 (1.749‐3.544)   .000                    2.339 (1.641‐3.334)   .000
  ELNs                                                                                   
  ≤50                (Ref)                                         (Ref)                  
  \>50               0.769 (0.660‐0.896)   .000                    0.794 (0.674‐0.937)   .006
  MLNR                                                                                   
  0                  (Ref)                 .000                    (Ref)                  
  (0, 0.065)         1.858 (1.605‐2.150)   .000                    1.985 (1.654‐2.382)   .000
  \>0.065            2.523 (2.196‐2.900)   .000                    2.307 (1.946‐2.735)   .000
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3.3. Generation of a new survival‐predicting model {#cam42902-sec-0012}
--------------------------------------------------

Based on the result of multivariate analysis, prognostic factors, including ELNs, MLNR, age, T stage were utilized to construct a new survival predicting model (Figure [2](#cam42902-fig-0002){ref-type="fig"}). Each independent parameter was allotted a score, and the total risk point can be calculated by adding all the variable scores. Finally, the probability of death in each patient can be directedly read by drawing a plummet line.

![Overall survival‐predicting model for LC patients who had undergone laryngectomy and lymphadenectomy](CAM4-9-3006-g002){#cam42902-fig-0002}

The predicting performance of the model was assessed using the C‐index and calibration curve, and internally validated in the training set. In the training set, a C‐index of 0.683 (95% CI: 0.663‐0.703) was observed for the model, which was higher than that of the AJCC TNM stage system (7th) (0.641, 95% CI: 0.621‐0.661). For the testing set, the survival‐predicting performance of our model (0.662, 95% CI: 0.631‐0.693) was still superior to that of the AJCC TNM stage system (7th) (0.641, 95% CI: 0.621‐0.661). The calibration curves showed that the predicted OS by our model matched well with clinically observed OS in both training set and testing set (Figure [3](#cam42902-fig-0003){ref-type="fig"}A,B).

![The calibration curve of the model for predicting overall survival in the training set (A) and in the testing set (B). Model‐predicted OS is plotted on the x‐axis, and actual on the y‐axis. Comparison of Kaplan‐Meier curves between subgroups in the training set (C) and in the testing set (D)](CAM4-9-3006-g003){#cam42902-fig-0003}

In addition to predicting probability of OS, this model was also used to classify patients into three subgroups with the incremental risk of death based on their total scores. The stratification strategy was as follows: (a) high‐risk group: \>210 (n = 621), (b) moderate‐risk group: (150, 210\] (n = 696), and 3) low‐risk group: ≤150 (n = 805). Significant survival differences were observed between subgroups in the training set and validating set (Figure [3](#cam42902-fig-0003){ref-type="fig"}C,D).

3.4. Clinical value of the novel classification system {#cam42902-sec-0013}
------------------------------------------------------

Overall, the 3‐year and 5‐year OS of patients with resected laryngeal carcinoma were 63.8% and 51.1%, respectively. Kaplan‐Meier analysis and the log‐rank test showed that patients receiving adjuvant therapy had even worse survival outcomes than those receiving surgery alone (*P* = .031, Figure [4](#cam42902-fig-0004){ref-type="fig"}A). It was imperative to select suitable patients for adjuvant therapy in case of the occurrence of excessive medical treatment.

![The Kaplan‐Meier curves of OS for patients after laryngectomy and lymphadenectomy. The prognostic value of adjuvant therapy (AT) in total patient cohort (n = 2122, A), low‐risk group (n = 805, B), moderate‐risk group (n = 696, C), and high‐risk group (n = 621, D)](CAM4-9-3006-g004){#cam42902-fig-0004}

Next, we further compared the survival outcomes between patients with and without adjuvant treatment in each subgroup based on our novel survival‐predicting model. Notably, only patients in high‐risk group could benefit from adjuvant treatment (*P* \< .001, Figure [4](#cam42902-fig-0004){ref-type="fig"}D), whereas patients in other groups did not (Figure [4](#cam42902-fig-0004){ref-type="fig"}B,C). In the high‐risk group, the 3‐year survival of patients receiving adjuvant therapy was 47.2%, which was higher than that of patients receiving surgery alone (37.3%). Notably, for patients in low‐risk group, the long‐term survival outcomes of those receiving adjuvant therapy (10‐year OS: 43.0%) were even worse than those receiving surgery alone (10‐year OS: 56.8%). These findings supported that the stratification strategy could help to guide adjuvant treatment for patients with resected laryngeal cancer.

4. DISCUSSION {#cam42902-sec-0014}
=============

In this study, the data of patients with resected laryngeal carcinoma were retrieved from the SEER database to investigate the prognostic value of lymph node status. We found that lymphatic metastasis was relatively common among patients receiving both laryngectomy and lymphadenectomy, and there were more than 50% of patients who had at least one positive lymph node. Under this background, how to accurately evaluate the prognostic significance of lymph node status has become an urgent problem to be solved.

Lymph node status is relatively important for laryngeal cancer, including the number of examined lymph nodes and the ratio of metastatic lymph nodes. Notably, the exact number of pathologically confirmed lymph nodes has been incorporated into the AJCC TNM stage system.[14](#cam42902-bib-0014){ref-type="ref"} However, accurate quantification of metastatic lymph nodes largely depends on a sufficient number of ELNs. When the number of harvested lymph nodes is insufficient, potential positive lymph nodes may be ignored, which may result in the overestimation of oncological outcomes and affect the decision for subsequent treatment. The finding of our study suggested that 50 was considered as the optimal cut‐off value of ELNs for patients with resected laryngeal cancer. The 10‐year cumulative incidence of all‐cause of death in patients with ELNs\> 50 was 70.0%, whereas in the meantime a 4.8% risk increment of that in patients with ELNs ≤50. This finding supported that systematic lymphadenectomy (ELNs\> 50) could help improve the oncological outcomes of patients with laryngeal carcinoma.

Besides, the ratio of metastatic lymph nodes was also found to be an important prognostic factor for laryngeal cancer and many other cancers.[8](#cam42902-bib-0008){ref-type="ref"}, [15](#cam42902-bib-0015){ref-type="ref"} Prabhu et al indicted higher MLNR (\>0.20) were associated with a higher risk of locoregional recurrence and death in patients with head and neck carcinoma after primary surgical resection.[16](#cam42902-bib-0016){ref-type="ref"} Ryu et al also identified MLNR as an independent prognostic factor of cancer‐specific mortality in pN+ patients with laryngeal squamous cell cancer after laryngectomy.[17](#cam42902-bib-0017){ref-type="ref"} Thus, in this study, we jointly use ELNs, MLNR, and other clinicopathological features (age and T stage) to construct a novel survival‐predicting model, which was superior in predicting oncological outcomes of patients with resected laryngeal cancer. Notably, we further proposed a novel patient classification strategy based on the model. Patients were stratified into three subgroups with different risk of death. Kaplan‐Meier analysis and log‐rank tests showed significant survival differences between subgroups.

The purpose of adjuvant therapy should be the elimination of subclinical lesions. However, the adverse effects it may induce limit its application in most patients. The implementation of adjuvant therapy is still in the dilemma of the potential risk of undertreatment and excessive medical treatment. Agencies hold various opinions upon the role of adjuvant therapy for patients with resected laryngeal carcinoma. For instance, the American College of Radiology (ACR) recommends adjuvant treatment for advanced‐stage laryngeal cancer,[18](#cam42902-bib-0018){ref-type="ref"} whereas the National Comprehensive Cancer Network (NCCN) considers adjuvant therapy as an optimal option only for patients with certain adverse features, such as extracapsular nodal spread and positive margin.[19](#cam42902-bib-0019){ref-type="ref"} In this study, the survival outcomes of patients receiving surgery alone were even better than those receiving adjuvant therapy after initial surgical resection. From our perspective, this might be caused by two reasons, that is patients who were suggested to receive adjuvant therapy had more aggressive tumor progression in most cases and the adverse effects of adjuvant treatment might impair the prognosis of patients who did not candidate for it. How to select candidates for adjuvant therapy remains controversial.

Theoretically speaking, the presence of subclinical foci is determined by tumor behavior and the extent of surgery. Tumor behavior can be reflected by MLNR and T stage to some extent. ELNs reflects the adequacy of resection clearance in a way. So, in this study, we jointly used ELNs, MLNR, T stage, and age to distinguish patients with potential subclinical lesions and predict the role of adjuvant therapy in different patients. Patients with resected laryngeal carcinoma were classified into three groups with increasing risk of death. Then we investigate the effect of adjuvant therapy in each group. Notably, only patients in the high‐risk group were found to benefit from adjuvant treatment significantly (*P* \< .001), so we strongly recommend patients in the high‐risk group as candidates for adjuvant therapy. While for patients in the moderate‐risk group, the survival difference was not statistically significant, so surgery alone and regular examination were recommended, and adjuvant treatment was only used for those with other adverse characteristics, such as positive margin and extracapsular extension. As for patients in the low‐risk group, adjuvant therapy was not beneficial and even impaired the long‐term survival of patients to some extent, so surgery alone was sufficient for those patients.

Our study still had several limitations that should be highlighted, including its retrospective nature and the potential selection biases. Furthermore, patients included in our study were treated in different medical centers. Therefore, the quality of operations and adjuvant treatments and the methods employed by pathologists for diagnosing metastatic lymph nodes were not unified, which might influence the results of our study to some extent. In addition, the data of our study were retrieved from the SEER database, which lacked the information of extranodal extension, so we failed to restage patients according to the 8th AJCC stage system and compare the predicting performance of our new model with that of the 8th AJCC staging classification. Further prospective studies are required to testify whether our new model is superior to the conventional AJCC 8th TNM staging system in stratifying patients and in determining the value of adjuvant therapy after the initial surgery. Finally, although univariate analysis showed that primary location was not an independent prognostic factor for patients with resected laryngeal cancer in our study, other studies have indicated that each location corresponds to a different pattern of regional spread as well as different overall survival.[2](#cam42902-bib-0002){ref-type="ref"}, [4](#cam42902-bib-0004){ref-type="ref"} If all sublocations are included together, there may exist over or infra estimation of the real overall survival. Further prospective studies are also required to testify its real estimation capacity in each sublocation, respectively. Nevertheless, our study was valuable and was the first to jointly use lymph nodes statue and other clinicopathological characteristics to evaluate the prognosis of patients after laryngectomy and lymphadenectomy and predict the prognostic value of adjuvant therapy.

5. CONCLUSION {#cam42902-sec-0015}
=============

In this large population‐based study, we proposed a novel model to predict the survival outcomes for patients with resected laryngeal carcinoma and assist in the decision making of adjuvant treatment. Further studies to validate and improve this model were warranted.
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